Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649112 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
A Phase 1 study, sponsored by Precision BioSciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04649112 is a Phase 1 study that has completed, run by Precision BioSciences. The registered enrollment target is 13 participants.
The verdict
NCT04649112, a Phase 1 study, has completed, sponsored by Precision BioSciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
Interventions
- GENETIC PBCAR19B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649112
The ClinicalTrials.gov registry entry for NCT04649112 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Precision BioSciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PBCAR19B is the first listed.
NCT04649112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04649112 about?
NCT04649112 is a clinical study titled "Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies". This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
What is the current status of trial NCT04649112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-06-16. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT04649112?
The interventions under investigation include: PBCAR19B (GENETIC).
Who is sponsoring clinical trial NCT04649112?
This trial is sponsored by Precision BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.